{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:11:30Z","timestamp":1791882690374,"version":"4.3.4"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020502","name":"District of Columbia Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020502","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015466","name":"Milken Institute School of Public Health","doi-asserted-by":"publisher","award":["CW75880"],"award-info":[{"award-number":["CW75880"]}],"id":[{"id":"10.13039\/100015466","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015466","name":"Milken Institute School of Public Health","doi-asserted-by":"publisher","award":["CDC-RFA-PS22-220103CONT24"],"award-info":[{"award-number":["CDC-RFA-PS22-220103CONT24"]}],"id":[{"id":"10.13039\/100015466","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>People who inject drugs (PWID) face multilevel barriers to adhering to daily oral preexposure prophylaxis (PrEP). Long-acting injectable (LAI) PrEP may help overcome some of these barriers. Understanding willingness among PWID to take LAI PrEP and preferences for PrEP modality is important to promote LAI PrEP when it becomes available to them.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed data from the 2018 National HIV Behavioral Surveillance PWID data collection cycle in Washington, DC. Respondent-driven sampling weighted proportions and correlates of willingness to take LAI PrEP and preference for LAI PrEP versus daily oral PrEP were reported, overall and stratified by gender.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 402 PWID, 69.1% reported being extremely likely\/likely to take LAI PrEP; 52.4% preferred LAI PrEP over daily oral PrEP. Being female and uninsured were associated with higher odds of willingness to take LAI PrEP. Having no\/low income and past-year sexual violence were associated with preferring LAI PrEP over daily oral PrEP. Men who inject drugs who were aware of PrEP had higher odds to prefer LAI PrEP over daily oral PrEP. Women who inject drugs (WWID) reporting no\/low income, sexual violence, and receptive needle sharing were more likely to prefer LAI PrEP over daily oral PrEP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PWID in Washington, DC reported high willingness to take LAI PrEP; half reported preferring LAI PrEP. Improving education about PrEP is important for healthcare providers and PWID. Subgroups of WWID experiencing sexual violence may benefit from LAI PrEP. Human immunodeficiency virus prevention programs for PWID should consider gender differences when implementing LAI PrEP.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf389","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T14:13:04Z","timestamp":1751551984000},"source":"Crossref","is-referenced-by-count":3,"title":["Willingness to Take Long-Acting Injectable Preexposure Prophylaxis (PrEP) and Preference for PrEP Modalities Among People Who Inject Drugs in Washington, DC"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1524-4775","authenticated-orcid":false,"given":"Xinyi","family":"Li","sequence":"first","affiliation":[{"name":"Milken Institute School of Public Health, George Washington University , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Bornstein","sequence":"additional","affiliation":[{"name":"Milken Institute School of Public Health, George Washington University , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6742-549X","authenticated-orcid":false,"given":"Madhu","family":"Balachandran","sequence":"additional","affiliation":[{"name":"Milken Institute School of Public Health, George Washington University , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6359-987X","authenticated-orcid":false,"given":"Manya","family":"Magnus","sequence":"additional","affiliation":[{"name":"Milken Institute School of Public Health, George Washington University , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Drezner","sequence":"additional","affiliation":[{"name":"HIV\/AIDS, Hepatitis, STD and TB Administration, District of Columbia Department of Health , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittani","family":"Saafir-Callaway","sequence":"additional","affiliation":[{"name":"HIV\/AIDS, Hepatitis, STD and TB Administration, District of Columbia Department of Health , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kuo","sequence":"additional","affiliation":[{"name":"Milken Institute School of Public Health, George Washington University , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"2025071604212256200_ofaf389-B1","author":"Centers for Disease Control and Prevention"},{"key":"2025071604212256200_ofaf389-B2","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"key":"2025071604212256200_ofaf389-B3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/QAD.0000000000000613","article-title":"The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs","volume":"29","author":"Martin","year":"2015","journal-title":"AIDS"},{"key":"2025071604212256200_ofaf389-B4","author":"Centers for Disease Control and Prevention"},{"key":"2025071604212256200_ofaf389-B5","author":"Centers for Disease Control and Prevention"},{"key":"2025071604212256200_ofaf389-B6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11606-020-06201-6","article-title":"\u2018Health is on the back burner:\u2019 multilevel barriers and facilitators to primary care among people who inject drugs","volume":"36","author":"Motavalli","year":"2021","journal-title":"J Gen Intern Med"},{"key":"2025071604212256200_ofaf389-B7","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s10461-020-02988-x","article-title":"The pre-exposure prophylaxis (PrEP) care cascade in people who inject drugs: a systematic review","volume":"25","author":"Mistler","year":"2021","journal-title":"AIDS Behav"},{"key":"2025071604212256200_ofaf389-B8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12954-018-0263-5","article-title":"Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs","volume":"15","author":"Biello","year":"2018","journal-title":"Harm Reduct J"},{"key":"2025071604212256200_ofaf389-B9","author":"US Food and Drug Administration"},{"key":"2025071604212256200_ofaf389-B10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2025071604212256200_ofaf389-B11","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"key":"2025071604212256200_ofaf389-B12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/COH.0000000000000734","article-title":"Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review","volume":"17","author":"Sued","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"2025071604212256200_ofaf389-B13","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s12325-020-01295-0","article-title":"Barriers to the wider use of pre-exposure prophylaxis in the United States: a narrative review","volume":"37","author":"Mayer","year":"2020","journal-title":"Adv Ther"},{"key":"2025071604212256200_ofaf389-B14","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1080\/09540121.2019.1587356","article-title":"A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs","volume":"31","author":"Biello","year":"2019","journal-title":"AIDS Care"},{"key":"2025071604212256200_ofaf389-B15","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1007\/s10461-021-03483-7","article-title":"Long-acting injectable ART and PrEP among women in six cities across the United States: a qualitative analysis of who would benefit the most","volume":"26","author":"Philbin","year":"2022","journal-title":"AIDS Behav"},{"key":"2025071604212256200_ofaf389-B16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/apc.2020.0164","article-title":"A qualitative exploration of women's interest in long-acting injectable antiretroviral therapy across six cities in the Women's Interagency HIV Study: intersections with current and past injectable medication and substance use","volume":"35","author":"Philbin","year":"2021","journal-title":"AIDS Patient Care STDs"},{"key":"2025071604212256200_ofaf389-B17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1089\/apc.2018.0126","article-title":"Limited knowledge and mixed interest in pre-exposure prophylaxis for HIV prevention among people who inject drugs","volume":"32","author":"Bazzi","year":"2018","journal-title":"AIDS Patient Care STDS"},{"key":"2025071604212256200_ofaf389-B18","doi-asserted-by":"crossref","first-page":"e0209484","DOI":"10.1371\/journal.pone.0209484","article-title":"Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men","volume":"13","author":"Patel","year":"2018","journal-title":"PLoS One"},{"key":"2025071604212256200_ofaf389-B19","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1007\/s10461-021-03571-8","article-title":"Preferences for HIV preexposure prophylaxis products among Black women in the U.S","volume":"26","author":"Irie","year":"2022","journal-title":"AIDS Behav"},{"key":"2025071604212256200_ofaf389-B20","doi-asserted-by":"crossref","first-page":"111133","DOI":"10.1016\/j.drugalcdep.2024.111133","article-title":"PrEP for people who use opioids: a NIDA Clinical Trials Network survey study in southern U.S. cities where HIV incidence is high","volume":"257","author":"Hatch","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"2025071604212256200_ofaf389-B21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1089\/apc.2022.0068","article-title":"Long-acting injectable human immunodeficiency virus pre-exposure prophylaxis preferred over other modalities among people who inject drugs: findings from a qualitative study in California","volume":"36","author":"Bazzi","year":"2022","journal-title":"AIDS Patient Care STDS"},{"key":"2025071604212256200_ofaf389-B22","author":"The International Network of People Who Use Drugs"},{"issue":"Suppl 1","key":"2025071604212256200_ofaf389-B23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/00333549071220S108","article-title":"Developing an HIV behavioral surveillance system for injecting drug users: the National HIV Behavioral Surveillance System","volume":"122","author":"Lansky","year":"2007","journal-title":"Public Health Rep"},{"key":"2025071604212256200_ofaf389-B24","author":"Bennett"},{"key":"2025071604212256200_ofaf389-B25","first-page":"157","article-title":"Differing HIV risks and prevention needs among men and women injection drug users (IDU) in the District of Columbia","volume":"90","author":"Magnus","year":"2013","journal-title":"J Urban Health Bull N Y Acad Med"},{"key":"2025071604212256200_ofaf389-B26","doi-asserted-by":"crossref","first-page":"e0183521","DOI":"10.1371\/journal.pone.0183521","article-title":"Willingness of community-recruited men who have sex with men in Washington, DC to use long-acting injectable HIV pre-exposure prophylaxis","volume":"12","author":"Levy","year":"2017","journal-title":"PLoS One"},{"key":"2025071604212256200_ofaf389-B27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2016.02.044","article-title":"Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC","volume":"164","author":"Kuo","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"2025071604212256200_ofaf389-B28","volume-title":"SAS\/STAT 15.3 user's guide","author":"SAS Institute Inc","year":"2023"},{"key":"2025071604212256200_ofaf389-B29","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s10461-018-2305-0","article-title":"A review of approaches used to increase awareness of pre-exposure prophylaxis (PrEP) in the United States","volume":"23","author":"Sophus","year":"2019","journal-title":"AIDS Behav"},{"key":"2025071604212256200_ofaf389-B30","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1080\/09540121.2019.1587352","article-title":"Exploring new and existing PrEP modalities among female sex workers and women who inject drugs in a U.S. city","volume":"31","author":"Footer","year":"2019","journal-title":"AIDS Care"},{"key":"2025071604212256200_ofaf389-B31","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s10508-022-02323-6","article-title":"Association between dual partnership and sexual and injecting behaviors among persons who inject drugs in 23 US cities, 2018","volume":"51","author":"Li","year":"2022","journal-title":"Arch Sex Behav"},{"key":"2025071604212256200_ofaf389-B32","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1186\/s12879-022-07572-3","article-title":"Acceptability of injectable pre-exposure prophylaxis among people who inject drugs in three urban U.S. settings","volume":"22","author":"King","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2025071604212256200_ofaf389-B33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1089\/apc.2016.0098","article-title":"The potential of pre-exposure prophylaxis for women in violent relationships","volume":"30","author":"Braksmajer","year":"2016","journal-title":"AIDS Patient Care STDS"},{"key":"2025071604212256200_ofaf389-B34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/QAI.0000000000001093","article-title":"Intimate partner violence and adherence to HIV pre-exposure prophylaxis (PrEP) in African women in HIV serodiscordant relationships: a prospective cohort study","volume":"73","author":"Roberts","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025071604212256200_ofaf389-B35","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1089\/jwh.2011.3328","article-title":"Sexual infidelity as trigger for intimate partner violence","volume":"21","author":"Nemeth","year":"2012","journal-title":"J Womens Health (Larchmt)"},{"key":"2025071604212256200_ofaf389-B36","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.1097\/QAI.0000000000001415","article-title":"Differences in awareness of pre-exposure prophylaxis and post-exposure prophylaxis among groups at-risk for HIV in New York State: New York City and Long Island, NY, 2011\u20132013","volume":"75","author":"Walters","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025071604212256200_ofaf389-B37","doi-asserted-by":"crossref","first-page":"23259582251336662","DOI":"10.1177\/23259582251336662","article-title":"Understanding intentions to discuss long-acting injectable pre-exposure prophylaxis with healthcare providers among Black and Hispanic gay and bisexual men in Texas","volume":"24","author":"Okafor","year":"2025","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2025071604212256200_ofaf389-B38","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12160-010-9200-x","article-title":"Longitudinal relationships between antiretroviral treatment adherence and discrimination due to HIV-serostatus, race, and sexual orientation among African-American men with HIV","volume":"40","author":"Bogart","year":"2010","journal-title":"Ann Behav Med"},{"key":"2025071604212256200_ofaf389-B39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","article-title":"Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review","volume":"131","author":"van Boekel","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"2025071604212256200_ofaf389-B40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","article-title":"\u2018They look at us like junkies': influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City","volume":"17","author":"Muncan","year":"2020","journal-title":"Harm Reduct J"},{"key":"2025071604212256200_ofaf389-B41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1521\/aeap.2019.31.4.363","article-title":"Medical providers and harm reduction views on pre-exposure prophylaxis for HIV prevention among people who inject drugs","volume":"31","author":"Hershow","year":"2019","journal-title":"AIDS Educ Prev"},{"key":"2025071604212256200_ofaf389-B42","doi-asserted-by":"crossref","first-page":"e0262926","DOI":"10.1371\/journal.pone.0262926","article-title":"Perspectives on preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: a qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County","volume":"17","author":"Jolayemi","year":"2022","journal-title":"PLoS One"},{"key":"2025071604212256200_ofaf389-B43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/apc.2018.0166","article-title":"Considering stigma in the provision of HIV pre-exposure prophylaxis: reflections from current prescribers","volume":"33","author":"Calabrese","year":"2019","journal-title":"AIDS Patient Care STDS"},{"key":"2025071604212256200_ofaf389-B44","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1080\/09540121.2016.1153595","article-title":"HIV providers' likelihood to prescribe pre-exposure prophylaxis (PrEP) for HIV prevention differs by patient type: a short report","volume":"28","author":"Adams","year":"2016","journal-title":"AIDS Care"},{"key":"2025071604212256200_ofaf389-B45","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s10461-016-1612-6","article-title":"Primary care physicians' willingness to prescribe HIV pre-exposure prophylaxis for people who inject drugs","volume":"21","author":"Edelman","year":"2017","journal-title":"AIDS Behav"},{"key":"2025071604212256200_ofaf389-B46","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s10461-013-0675-x","article-title":"The impact of patient race on clinical decisions related to prescribing HIV pre-exposure prophylaxis (PrEP): assumptions about sexual risk compensation and implications for access","volume":"18","author":"Calabrese","year":"2014","journal-title":"AIDS Behav"},{"key":"2025071604212256200_ofaf389-B47","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/hiv.13756","article-title":"Transitions in treatment: a systematic review and meta-aggregation of preferences and barriers in switching from oral to long-acting injectable antiretroviral therapy among people living with HIV and stakeholders","volume":"26","author":"Hu","year":"2025","journal-title":"HIV Med"},{"key":"2025071604212256200_ofaf389-B48","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/hiv.13451","article-title":"Long-acting injectable cabotegravir for PrEP: a game-changer in HIV prevention?","volume":"24","author":"Liegeon","year":"2023","journal-title":"HIV Med"},{"key":"2025071604212256200_ofaf389-B49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12954-023-00729-6","article-title":"Pre-exposure prophylaxis (PrEP) for HIV prevention among people who inject drugs: a global mapping of service delivery","volume":"20","author":"Shaw","year":"2023","journal-title":"Harm Reduct J"},{"key":"2025071604212256200_ofaf389-B50","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s10461-024-04598-3","article-title":"Long-acting injectable PrEP for people who inject drugs at a syringe services program: a qualitative acceptability and feasibility study","volume":"29","author":"Suarez","year":"2025","journal-title":"AIDS Behav"},{"issue":"5 Suppl 1","key":"2025071604212256200_ofaf389-B51","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.amepre.2021.05.044","article-title":"Syringe services programs' role in ending the HIV epidemic in the U.S.: why we cannot do it without them","volume":"61","author":"Broz","year":"2021","journal-title":"Am J Prev Med"},{"key":"2025071604212256200_ofaf389-B52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/ije\/dyt243","article-title":"Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis","volume":"43","author":"Aspinall","year":"2014","journal-title":"Int J Epidemiol"},{"key":"2025071604212256200_ofaf389-B53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12889-017-4210-2","article-title":"Effectiveness of needle and syringe programmes in people who inject drugs\u2014an overview of systematic reviews","volume":"17","author":"Fernandes","year":"2017","journal-title":"BMC Public Health"},{"key":"2025071604212256200_ofaf389-B54","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.drugpo.2015.08.018","article-title":"Trust and people who inject drugs: the perspectives of clients and staff of needle syringe programs","volume":"27","author":"Treloar","year":"2016","journal-title":"Int J Drug Policy"},{"key":"2025071604212256200_ofaf389-B55","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1007\/s10461-021-03227-7","article-title":"Use of pre-exposure prophylaxis among people who inject drugs: exploratory findings of the interaction between race, homelessness, and trust","volume":"25","author":"Zhou","year":"2021","journal-title":"AIDS Behav"},{"key":"2025071604212256200_ofaf389-B56","first-page":"5","article-title":"Factors that influence perception of HIV risk and willingness to use pre-exposure prophylaxis in people who inject drugs","volume":"3","author":"Egorova","year":"2021","journal-title":"J Maine Med Cent"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf389\/63662100\/ofaf389.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/7\/ofaf389\/63662100\/ofaf389.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/7\/ofaf389\/63662100\/ofaf389.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T08:21:46Z","timestamp":1752654106000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf389\/8185534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf389","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,30]]},"article-number":"ofaf389"}}